CL2019001465A1 - Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. - Google Patents
Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.Info
- Publication number
- CL2019001465A1 CL2019001465A1 CL2019001465A CL2019001465A CL2019001465A1 CL 2019001465 A1 CL2019001465 A1 CL 2019001465A1 CL 2019001465 A CL2019001465 A CL 2019001465A CL 2019001465 A CL2019001465 A CL 2019001465A CL 2019001465 A1 CL2019001465 A1 CL 2019001465A1
- Authority
- CL
- Chile
- Prior art keywords
- glucagon
- trigonal
- glp1
- new compounds
- gip receptors
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title abstract 3
- 108060003199 Glucagon Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 3
- 229960004666 glucagon Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NUEVOS COMPUESTOS COMO AGONISTAS PEPTÍDICOS TRIGONALES DE LOS RECEPTORES DE GLP1/GLUCAGÓN/GIP. LA PRESENTE INVENCIÓN SE REFIERE A AGONISTAS TRIGONALES DE LOS RECEPTORES DE GLP-1 / GLUCAGÓN / GIP Y A SU USO MÉDICO, POR EJEMPLO, EN EL TRATAMIENTO DE TRASTORNOS DEL SÍNDROME METABÓLICO, INCLUYENDO DIABETES Y OBESIDAD, ASÍ COMO PARA LA REDUCCIÓN DEL EXCESO DE INGESTA DE ALIMENTOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306604 | 2016-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001465A1 true CL2019001465A1 (es) | 2019-10-18 |
Family
ID=57542935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001465A CL2019001465A1 (es) | 2016-12-02 | 2019-05-30 | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10538567B2 (es) |
| EP (1) | EP3548508B1 (es) |
| JP (1) | JP7100033B2 (es) |
| KR (1) | KR102576872B1 (es) |
| CN (1) | CN110023329B (es) |
| AR (1) | AR110300A1 (es) |
| AU (1) | AU2017367173B2 (es) |
| BR (1) | BR112019011228A2 (es) |
| CA (1) | CA3045377A1 (es) |
| CL (1) | CL2019001465A1 (es) |
| CO (1) | CO2019006917A2 (es) |
| CR (1) | CR20190313A (es) |
| DO (1) | DOP2019000068A (es) |
| EA (1) | EA201991345A1 (es) |
| EC (1) | ECSP19046893A (es) |
| IL (1) | IL266984A (es) |
| MA (1) | MA46955A (es) |
| MX (1) | MX2019006429A (es) |
| PE (1) | PE20191143A1 (es) |
| PH (1) | PH12019501216A1 (es) |
| TW (1) | TW201833132A (es) |
| UY (1) | UY37506A (es) |
| WO (1) | WO2018100134A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| WO2019197466A1 (en) | 2018-04-10 | 2019-10-17 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
| AU2019250362B2 (en) | 2018-04-10 | 2025-11-06 | Sanofi-Aventis Deutschland Gmbh | Lixisenatide synthesis with capping |
| TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物 |
| WO2020130749A1 (ko) * | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 |
| WO2021066600A1 (ko) * | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| TW202140058A (zh) * | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| AU2021322137A1 (en) | 2020-08-07 | 2023-01-19 | Boehringer Ingelheim International Gmbh | Soluble NPY2 receptor agonists |
| WO2022035302A1 (ko) * | 2020-08-14 | 2022-02-17 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 |
| CN114349828B (zh) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | Glp-1/胰高血糖素受体双重激动剂及其应用 |
| TW202241492A (zh) * | 2020-12-16 | 2022-11-01 | 丹麥商西蘭製藥公司 | Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物 |
| ES3019509T3 (en) * | 2020-12-16 | 2025-05-20 | Zealand Pharma As | Pharmaceutical composition of glp-1/glp-2 dual agonists |
| KR20240027045A (ko) * | 2021-06-25 | 2024-02-29 | 일라이 릴리 앤드 캄파니 | 폐쇄성 수면 무호흡의 치료 방법 |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| US20250296960A1 (en) * | 2022-05-27 | 2025-09-25 | D&D Pharmatech Inc. | Peptide compositions and methods of use thereof |
| CN120795089A (zh) * | 2022-09-28 | 2025-10-17 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
| CN120530127A (zh) * | 2022-12-23 | 2025-08-22 | 韩美药品株式会社 | 新型三重glp-1/gip/胰高血糖素受体激动剂及包括其的用于预防或治疗肥胖症的药物组合物 |
| WO2025049610A1 (en) * | 2023-08-28 | 2025-03-06 | Shattuck Labs, Inc. | Multi-action peptides |
| CN117586374B (zh) * | 2023-10-07 | 2024-11-29 | 深圳湾实验室 | Glp-1r/gipr/gcgr三重激动剂类似物及其用途 |
| CN119241684B (zh) * | 2024-11-22 | 2025-02-25 | 徐州医科大学 | 一种肠促胰岛素类似物及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544657B2 (en) | 2002-10-02 | 2009-06-09 | Zealand Pharma A/S | Stabilized Exendin-4 compounds |
| US20080019911A1 (en) * | 2005-04-20 | 2008-01-24 | Aimin Xu | Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4 |
| ATE553124T1 (de) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| RU2012101274A (ru) | 2009-06-16 | 2013-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Соединения глюкагона, активные в отношении рецептора gip |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| CN103458920B (zh) | 2010-12-22 | 2016-07-06 | 印第安那大学科技研究公司 | 表现出gip受体活性的胰高血糖素类似物 |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| SI2864350T1 (en) | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SI2934568T1 (en) * | 2012-12-21 | 2018-03-30 | Sanofi | Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| EP3080151A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609800A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物 |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| AR110301A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
-
2017
- 2017-11-30 TW TW106141759A patent/TW201833132A/zh unknown
- 2017-11-30 AR ARP170103362A patent/AR110300A1/es unknown
- 2017-12-01 MX MX2019006429A patent/MX2019006429A/es unknown
- 2017-12-01 KR KR1020197018943A patent/KR102576872B1/ko active Active
- 2017-12-01 CN CN201780074707.9A patent/CN110023329B/zh active Active
- 2017-12-01 PE PE2019000905A patent/PE20191143A1/es unknown
- 2017-12-01 EP EP17821804.6A patent/EP3548508B1/en active Active
- 2017-12-01 UY UY0001037506A patent/UY37506A/es unknown
- 2017-12-01 CA CA3045377A patent/CA3045377A1/en not_active Abandoned
- 2017-12-01 WO PCT/EP2017/081125 patent/WO2018100134A1/en not_active Ceased
- 2017-12-01 US US15/829,680 patent/US10538567B2/en active Active
- 2017-12-01 CR CR20190313A patent/CR20190313A/es unknown
- 2017-12-01 MA MA046955A patent/MA46955A/fr unknown
- 2017-12-01 BR BR112019011228A patent/BR112019011228A2/pt not_active Application Discontinuation
- 2017-12-01 JP JP2019529535A patent/JP7100033B2/ja active Active
- 2017-12-01 EA EA201991345A patent/EA201991345A1/ru unknown
- 2017-12-01 AU AU2017367173A patent/AU2017367173B2/en active Active
-
2019
- 2019-03-19 DO DO2019000068A patent/DOP2019000068A/es unknown
- 2019-05-29 IL IL266984A patent/IL266984A/en unknown
- 2019-05-30 CL CL2019001465A patent/CL2019001465A1/es unknown
- 2019-05-31 PH PH12019501216A patent/PH12019501216A1/en unknown
- 2019-06-27 CO CONC2019/0006917A patent/CO2019006917A2/es unknown
- 2019-07-01 EC ECSENADI201946893A patent/ECSP19046893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019006917A2 (es) | 2019-07-10 |
| DOP2019000068A (es) | 2019-05-31 |
| BR112019011228A2 (pt) | 2019-10-15 |
| EA201991345A1 (ru) | 2019-11-29 |
| AU2017367173A1 (en) | 2019-07-18 |
| IL266984A (en) | 2019-07-31 |
| CR20190313A (es) | 2019-09-11 |
| CA3045377A1 (en) | 2018-06-07 |
| PE20191143A1 (es) | 2019-09-02 |
| AU2017367173B2 (en) | 2022-03-24 |
| MA46955A (fr) | 2021-05-19 |
| EP3548508A1 (en) | 2019-10-09 |
| CN110023329B (zh) | 2024-05-03 |
| JP2019536796A (ja) | 2019-12-19 |
| EP3548508B1 (en) | 2021-10-27 |
| US20180155406A1 (en) | 2018-06-07 |
| AR110300A1 (es) | 2019-03-13 |
| WO2018100134A1 (en) | 2018-06-07 |
| CN110023329A (zh) | 2019-07-16 |
| JP7100033B2 (ja) | 2022-07-12 |
| KR102576872B1 (ko) | 2023-09-12 |
| UY37506A (es) | 2018-06-29 |
| PH12019501216A1 (en) | 2019-08-19 |
| TW201833132A (zh) | 2018-09-16 |
| KR20190085141A (ko) | 2019-07-17 |
| ECSP19046893A (es) | 2019-07-31 |
| MX2019006429A (es) | 2019-08-21 |
| US10538567B2 (en) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001465A1 (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
| BR112019011144A2 (pt) | compostos como agonistas peptídicos de receptor de glp1/glucagon/gip | |
| UY35231A (es) | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| BR112016022754A2 (pt) | derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon | |
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| UY35072A (es) | Derivados de exendina-4 como agonistas duales de GLP1/glucagón | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| GT201700085A (es) | Coagonistas de los receptores del glucagón y de glp-1 | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| BR112016023039A2 (pt) | agonistas duplos dos receptores de glp-1 / glucagon derivados de exendina-4 | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| CL2020000166A1 (es) | Compuestos bifuncionales. | |
| CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| CR20170470A (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| MX394179B (es) | Liraglutida en afecciones cardiovasculares. | |
| AR103944A1 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 |